Asep Inc. has developed a novel diagnostic assay for the early and rapid risk assessment of sepsis, based on the detection of unique molecular signatures of sepsis specific to the immune response, rather than the presence of a pathogen.
This Rapid Diagnostic Test delivers results in ~1 hour, significantly improving sepsis survival rates.
Every Hour Counts
Greater sensitivity and specificity than the SIRS (Systemic Inflammatory Response Syndrome) criteria used today
Earlier recognition of sepsis, at a time when patients are admitted to the emergency room
Reliable test results for determining the most appropriate treatment to improve survival
Next-generation molecular diagnostic technology focusing on patient-specific immune response
The company has undertaken the largest-ever predictive clinical genomics study of early sepsis to validate our diagnostic technology.
>500 patient prospective multicentre clinical study confirms initial findings and refines the signature
Study results aid to extrapolate to additional patient populations (pediatrics, cancers, pancreatitis, etc.)
Correlate clinical symptoms with gene expression reflecting immune status
Work in patients with wide range of symptoms
Additional 400 patients study confirms relevance of Sepset ER™ to severe Covid disease
ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved